In short
Clinical trials investigating Anhydrous Caffeine are studying how it performs in different patient groups, with a focus on safety, efficacy, and key outcome measures. The trial data provided here includes studies in cancer, autoimmune disease, and chronic pain, mostly in adults. These studies help researchers learn whether the treatment works and how well it is tolerated.
Key points
- Clinical trial data linked to Anhydrous Caffeine was not provided directly, so the available records here describe other investigational treatments in several diseases. The studies include cancer, autoimmune disease, chronic pain, and blood cancers. Trial phases range from early Phase 1/2 studies to larger Phase 3 studies. The main outcomes include safety, side effects, disease response, pain scores, and disease activity measures. Some studies are completed, while others are authorised and may still be ongoing or planned.
Trial overview
The trial records provided for this article do not show a study directly testing Anhydrous Caffeine. Instead, they describe several clinical trials of other treatments in cancer, autoimmune disease, and chronic pain.
These studies are interventional trials, which means researchers give a treatment and then measure what happens.
Study populations and conditions
Several trials focus on people with lymphoma, including Hodgkin lymphoma, non-Hodgkin lymphoma, follicular lymphoma, marginal zone lymphoma, and indolent non-Hodgkin lymphoma.
Other studies include adults with systemic lupus erythematosus (SLE), which is a long-term autoimmune disease where the immune system attacks the body’s own tissues.
One Phase 3 study includes people with rheumatoid arthritis, a disease that causes joint inflammation and pain.
Another study looks at multiple myeloma, a cancer of plasma cells, and one Phase 3 trial studies chronic pain due to diabetic polyneuropathy, which is nerve pain related to diabetes.
One basket study includes several solid tumors: endometrial cancer, cervical cancer, prostate cancer, urothelial carcinoma, and ovarian cancer.
Trial phases and what they mean
The data includes Phase 1/2, Phase 2, and Phase 3 studies.
Phase 1/2 studies usually begin with safety checks and early testing of whether a treatment may work.
Phase 2 studies often look for early proof of benefit in a specific disease group, while still watching safety closely.
Phase 3 studies are larger and are used to confirm benefit and safety in bigger patient groups.
Main endpoints measured in the trials
In the lymphoma Phase 1/2 study, the main safety outcome was the number of dose-limiting toxicities, which are side effects serious enough to stop dose increases, along with the number and severity of adverse events.
The same study also measured overall response rate using Lugano criteria, which are rules doctors use to judge how well lymphoma responds to treatment.
In the diabetic polyneuropathy pain study, the main outcome was change in pain score on the Numeric Rating Scale from baseline to week 14.
The basket study in solid tumors measured safety by counting dose-limiting toxicities, adverse events, and treatment stops due to side effects, and it measured efficacy by complete or partial response and, in prostate cancer, changes in prostate-specific antigen, a protein made by the prostate gland.
The lupus study at Week 48 used the BICLA response, a composite score that combines several signs of disease improvement.
The long-term lupus study measured treatment-emergent adverse events, serious adverse events, and adverse events that led to permanent treatment discontinuation.
The rheumatoid arthritis study measured change in DAS28-CRP at Week 12, which is a score showing how active the arthritis is based on joints and inflammation markers.
The multiple myeloma imaging study measured sensitivity, meaning how well the scan found true disease lesions, by comparing results with other imaging, follow-up, or histology, which is tissue examination under a microscope.
The indolent non-Hodgkin lymphoma study measured objective response rate over a long follow-up period of up to 15 years.
Trial status and study size
Some records are marked Completed, which means the study has finished collecting data.
Other records are marked Authorised, which means the study has been approved and is not listed as completed in the provided data.
Enrollment ranged from 45 people in the multiple myeloma imaging study to 765 people in the long-term lupus study.
How to read these trial records
When reading a trial record, the most useful parts are the condition being studied, the phase, the number of participants, and the main outcome being measured.
If a study lists safety outcomes, it means researchers are checking for unwanted medical problems during the trial.
If a study lists response, pain score, or disease activity, it means researchers are trying to see whether the treatment helps the condition being studied.